Laureate Pharma has entered into a cGMP contract manufacturing agreement with Cytheris SA, a clinical stage biopharma focused on immune modulation. Laureate will manufacture Cytheris' lead product candidate, Interleukin-7 (IL-7), a fully glycosylated recombinant human protein and critical growth factor for immune T-cell recovery, for use in ongoing international clinical trials currently being conducted for treatment of HIV, HCV and cancer. Terms and conditions of the agreement were not disclosed.

"We are delighted that Cytheris has selected us again as their CMO, to manufacture IL-7 in support of their expanded clinical trial program. This is a testimonial to our successful partnership with our clients and our effort to achieve their total satisfaction in our ability to meet their manufacturing needs," said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate. "We will work with the Cytheris team very closely and help them realize the greatest potential of their IL-7 development and production program."

"As we move towards large scale production of our IL-7 biotherapeutic, we are pleased to continue our strong working relationship with Laureate Pharma," said Michel Morre, DVM, president and chief executive officer of Cytheris. "With Laureate's demonstrated skill in successful transfer of process technology, we look forward to continuing to work together in the process scale-up, engineering and clinical material production of IL-7 for our ongoing clinical trials investigating multiple indications."

News from our sister sites